Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H1 2018

 Published On: Feb, 2018 |    No of Pages: 141 |  Published By: Global Markets Direct | Format: PDF
Request Free Sample

Summary

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - CTLA4 also known as CD152 is a protein receptor found on the surface of T cells. It functions as an immune checkpoint and down regulates the immune system. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory co-receptor CD28. Inhibition of receptor acts as a major negative regulator of T-cell responses.

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) pipeline Target constitutes close to 43 molecules. Out of which approximately 42 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 5, 4, 1, 18, 9 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology and Infectious Disease which include indications Solid Tumor, Non-Small Cell Lung Cancer, Gastric Cancer, Bladder Cancer, Breast Cancer, Hepatocellular Carcinoma, Melanoma, Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Nasopharyngeal Cancer, Small-Cell Lung Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Anaplastic Thyroid Cancer, Cervical Cancer, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Gastroesophageal (GE) Junction Carcinomas, Germ Cell Tumors, Hematological Tumor, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Malignant Pleural Mesothelioma, Merkel Cell Carcinoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Multiple Myeloma (Kahler Disease), Muscle Invasive Bladder Cancer (MIBC), Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), Non-Hodgkin Lymphoma, Peritoneal Cancer, Renal Cell Carcinoma, Adrenal Gland Cancer, Adrenocortical Carcinoma (Adrenal Cortex Cancer), Advanced Malignancy, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colon Cancer, Dedifferentiated Liposarcoma, Dysgerminoma, Endometrial Cancer, Ependymoma, Esophageal Cancer, Ewing Sarcoma, Germinomatous (Seminomatous) Germ Cell Tumors, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, High-Grade Glioma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Human Immunodeficiency Virus (HIV) Infections (AIDS), Kaposi Sarcoma, Lymphoma, Malignant Fibrous Histiocytoma, Malignant Mesothelioma, Medullary Thyroid Cancer, Medulloblastoma, Metastatic Breast Cancer, Metastatic Cancer, Metastatic Colorectal Cancer, Metastatic Liver Cancer, Metastatic Lung Cancer, Metastatic Pancreatic Cancer, Metastatic Renal Cell Carcinoma, Metastatic Uveal Melanoma, Neuroblastoma, Neuroendocrine Tumors, Nongerminomatous (Nonseminomatous) Germ Cell Tumors, Oropharyngeal Cancer, Osteosarcoma, Ovarian Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Papillary Renal Cell Carcinoma, Pediatric Diffuse Intrinsic Pontine Glioma, Primitive Neuroectodermal Tumor (PNET), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rhabdomyosarcoma, Salivary Gland Cancer, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Ureter Cancer, Urethral Cancer, Urinary Tract Cancer, Vaginal Cancer and Vulvar Cancer.

The latest report Cytotoxic T Lymphocyte Protein 4 - Pipeline Review, H1 2018, outlays comprehensive information on the Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4)
- The report reviews Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Overview
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Companies Involved in Therapeutics Development
Aduro BioTech Inc
Agenus Inc
Alligator Bioscience AB
Bristol-Myers Squibb Co
Cold Genesys Inc
Crown Bioscience Inc
Five Prime Therapeutics Inc
GigaGen Inc
Immunocore Ltd
Immunwork Inc
Innovent Biologics Inc
JHL Biotech Inc
MacroGenics Inc
MedImmune LLC
Merck & Co Inc
OncoImmune Inc
PharmAbcine Inc
Premier Biomedical Inc
Replimune Ltd
Serometrix LLC
Sutro Biopharma Inc
Tikcro Technologies Ltd
Xencor Inc
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Drug Profiles
10B-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADU-1604 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AGEN-1884 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AGEN-2041 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotide to Inhibit CTLA4 for Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATOR-1015 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic to Antagonize CTLA4 and PD-1 for Solid Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic to Antagonize CTLA4 for Solid Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Antagonize CTLA-4 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Inhibit PD L1 and CTLA4 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986218 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986249 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CG-0070 + Immune Checkpoint Modulator - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CG-0161 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CNC-225 + CNC-118 + Anti-CTLA-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CS-1002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
durvalumab + IMCgp-100 + tremelimumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
durvalumab + tremelimumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FPT-155 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IBI-310 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ipilimumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ipilimumab + nivolumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JMW-3B3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KN-044 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MEDI-3617 + tremelimumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MGD-019 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-1308 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Antagonize 1 PD-1 and CTLA-4 for Solid Tumor and Hematological Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Antagonize CTLA-4 for Metastatic Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Antagonize CTLA-4 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize CTLA4 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize CTLA4 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize CTLA4 for Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit CTLA4 for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONC-392 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Antagonize CTLA4 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RP-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CTLA4 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tavolimab + tremelimumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TE-1254 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tremelimumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XmAb-20717 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XmAb-22841 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Dormant Products
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Discontinued Products
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Product Development Milestones
Featured News & Press Releases
Jan 25, 2018: Alligator Bioscience contracts Theradex Oncology as clinical CRO for the forthcoming Phase I study with ATOR-1015
Jan 22, 2018: European Commission Approves Bristol-Myers Squibb's Yervoy (ipilimumab) for Treatment of Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma
Jan 22, 2018: Agenus Announces Combination Clinical Trials of its Anti-CTLA4 (AGEN1884) & Anti-PD1 (AGEN2034)
Jan 20, 2018: Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrates Clinical Activity in Previously Treated Patients with dMMR or MSI-H Metastatic Colorectal Cancer
Dec 29, 2017: CStone's anti-CTLA-4 antibody CS1002 filed for clinical trial approval in Australia
Dec 18, 2017: Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Yervoy (ipilimumab) for the Treatment of Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma
Dec 15, 2017: CHMP Adopts Positive Opinion for Yervoy
Dec 13, 2017: U.S. Food and Drug Administration Accepts Bristol-Myers Squibb's Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in Intermediate- and Poor-Risk Patients with Advanced Renal Cell Carcinoma and Grants Priority Review
Nov 28, 2017: CytomX Therapeutics Announces FDA Acceptance of Investigational New Drug Application for CTLA-4 Probody Therapeutic
Nov 28, 2017: European Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in Intermediate- and Poor-Risk Patients with Advanced Renal Cell Carcinoma
Nov 10, 2017: Aduro Biotech Announces Promising Preclinical Data that Validate Anti-CTLA-4 Antibody ADU-1604
Nov 10, 2017: MacroGenics To Present Poster on MGD019 at 32nd Annual SITC Meeting 2017
Nov 09, 2017: Agenus To Present on Lead Antibody Program AGEN1884 (CTLA-4) at SITC 2017
Nov 08, 2017: Xencor Presents Preclinical Data on Tumor Microenvironment Targeting Bispecific XmAb20717 At Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting
Nov 07, 2017: Opdivo Plus Yervoy Combination Delivered Overall Survival Benefit Across PD-L1 Expression Levels in Intermediate- and Poor-Risk Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..3), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..4), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1)
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Products under Development by Companies, H1 2018 (Contd..5), H1 2018
Products under Development by Companies, H1 2018 (Contd..6), H1 2018
Products under Development by Companies, H1 2018 (Contd..7), H1 2018
Products under Development by Companies, H1 2018 (Contd..8), H1 2018
Products under Development by Companies, H1 2018 (Contd..9), H1 2018
Products under Development by Companies, H1 2018 (Contd..10), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Aduro BioTech Inc, H1 2018
Pipeline by Agenus Inc, H1 2018
Pipeline by Alligator Bioscience AB, H1 2018
Pipeline by Bristol-Myers Squibb Co, H1 2018
Pipeline by Cold Genesys Inc, H1 2018
Pipeline by Crown Bioscience Inc, H1 2018
Pipeline by Five Prime Therapeutics Inc, H1 2018
Pipeline by GigaGen Inc, H1 2018
Pipeline by Immunocore Ltd, H1 2018
Pipeline by Immunwork Inc, H1 2018
Pipeline by Innovent Biologics Inc, H1 2018
Pipeline by JHL Biotech Inc, H1 2018
Pipeline by MacroGenics Inc, H1 2018
Pipeline by MedImmune LLC, H1 2018
Pipeline by Merck & Co Inc, H1 2018
Pipeline by OncoImmune Inc, H1 2018
Pipeline by PharmAbcine Inc, H1 2018
Pipeline by Premier Biomedical Inc, H1 2018
Pipeline by Replimune Ltd, H1 2018
Pipeline by Serometrix LLC, H1 2018
Pipeline by Sutro Biopharma Inc, H1 2018
Pipeline by Tikcro Technologies Ltd, H1 2018
Pipeline by Xencor Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
Discontinued Products, H1 2018

List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018


If the above report does not have the information suitable for your business, we can provide custom research that can be lucrative for your business or enhance your profession.